Fri, Jan 30, 2015, 5:28 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

  • dooper55 dooper55 Oct 15, 2012 8:44 AM Flag

    Burrill Institutional Research Starts Stock Coverage on Omeros

    October 15th, 2012

    Investment analysts at Burrill Institutional Research began coverage on shares of Omeros Corp (NASDAQ: OMER) in a note issued to investors on Monday. The firm set an “outperform” rating and a $17.00 price target on the stock.

    Burrill Research commented, "In addition to PharmacoSurgery™, Omeros is developing a novel drug for addiction, as well as an antibody targeting multiple indications. Both of these programs are in early stages of development, but conveniently, a significant fraction of their development costs are covered by external grants. Additionally, Omeros created a unique platform for the discovery of novel GPCR (G-Protein Coupled Receptor) targeted drugs. At a time when the discovery of new compounds for GPCRs has slowed down significantly, Omeros could become a respected partner for the pharma industry."

22.24-1.1200(-4.79%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.